Women's Health Innovator Granata Bio Raises $14M Series A led by GV to Accelerate Fertility Biopharma Pipeline

Jan 16, 2024•almost 2 years ago

Amount Raised

$14 Million

BostonBiotechnology

Investors

Vibe BioAmboy VenturesAlumni VenturesGedeon RichterCooper SurgicalGv (Google Ventures)

Description

Granata Bio, Inc. announced the close of a $14M Series A funding round led by GV (Google Ventures) to accelerate its fertility biopharma pipeline.

Company Information

Company

Granata Bio

Location

289 ST GEORGE STREET

Boston, Massachusetts, United States

About

Granata Bio is a U.S. based biopharmaceutical company committed to advancing innovation in women's health and infertility. Founded in 2018, the company's pipeline includes a range of fertility therapies, with collaborations spanning multiple drug classes to address unmet needs in reproductive medicine. Granata Bio is the parent company of Oviva Therapeutics, Inc., a wholly owned subsidiary developing first-in-class therapeutics aimed at preserving ovarian function and extending female health span.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends